Jump to content

Radafaxine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 68.9.32.49 (talk) at 19:55, 9 February 2007. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Radafaxine is a drug currently in development by GlaxoSmithKline. Presently in various clinical trials, Radafaxine is being studied as a treatment for clinical depression, obesity, and neuropathic pain. Radafaxine is described as a norepinephrine-dopamine reuptake inhibitor (NDRI). It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's Wellbutrin. Therefore, Radafaxine builds on at least some of the properties of bupropion in humans. [1]

Unlike bupropion (which has a slightly higher effect on dopamine reuptake), Radafaxine seems to have a higher potentcy on norepinephrine. This, according to GlaxoSmithKline, may account for the increased effect of Radafaxine on pain and fatigue.[2]

At least one study suggests that Radafaxine has a low - abuse potential similar to bupropion.[3]

GlaxoSmithKline is targeting Radafaxine for regulatory filing in 2007. [4]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Radafaxine&oldid=106908291"